221 related articles for article (PubMed ID: 34449255)
1. Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjögren's Syndrome.
Kim J; Moon TK; Yoon HJ; Ji YS; Yoon KC
J Ocul Pharmacol Ther; 2021 Oct; 37(8):472-478. PubMed ID: 34449255
[No Abstract] [Full Text] [Related]
2. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
[TBL] [Abstract][Full Text] [Related]
3. Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome.
Cubuk MO; Ucgul AY; Ozgur A; Ozulken K; Yuksel E
Int Ophthalmol; 2021 Apr; 41(4):1479-1485. PubMed ID: 33484384
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.
Leonardi A; Van Setten G; Amrane M; Ismail D; Garrigue JS; Figueiredo FC; Baudouin C
Eur J Ophthalmol; 2016 Jun; 26(4):287-96. PubMed ID: 27055414
[TBL] [Abstract][Full Text] [Related]
6. Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye.
Daull P; Nagano T; Gros E; Feraille L; Barabino S; Garrigue JS
Curr Eye Res; 2021 Aug; 46(8):1096-1104. PubMed ID: 33588656
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Diquafosol Ophthalmic Solution in Non-Sjögren and Sjögren Syndrome Dry Eye Patients Unresponsive to Artificial Tear.
Jeon HS; Hyon JY
J Ocul Pharmacol Ther; 2016 Sep; 32(7):463-8. PubMed ID: 27294831
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
[TBL] [Abstract][Full Text] [Related]
9. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
[TBL] [Abstract][Full Text] [Related]
10. Topical fluorometholone treatment for ocular dryness in patients with Sjögren syndrome: a randomized clinical trial in China.
Lin T; Gong L
Medicine (Baltimore); 2015 Feb; 94(7):e551. PubMed ID: 25700323
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study.
Moscovici BK; Holzchuh R; Sakassegawa-Naves FE; Hoshino-Ruiz DR; Albers MB; Santo RM; Hida RY
Cont Lens Anterior Eye; 2015 Oct; 38(5):373-8. PubMed ID: 25956572
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen.
Chan YH; Sun CC
Taiwan J Ophthalmol; 2023; 13(1):68-74. PubMed ID: 37252163
[TBL] [Abstract][Full Text] [Related]
13. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction.
Prabhasawat P; Tesavibul N; Mahawong W
Cornea; 2012 Dec; 31(12):1386-93. PubMed ID: 23135530
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome.
Yavuz S; Asfuroğlu E; Bicakcigil M; Toker E
Rheumatol Int; 2011 Aug; 31(8):1045-9. PubMed ID: 20309693
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye.
Daull P; Feraille L; Barabino S; Cimbolini N; Antonelli S; Mauro V; Garrigue JS
Exp Eye Res; 2016 Dec; 153():159-164. PubMed ID: 27777121
[TBL] [Abstract][Full Text] [Related]
17. Increased corneal sub-basal nerve density in patients with Sjögren syndrome treated with topical cyclosporine A.
Levy O; Labbé A; Borderie V; Hamiche T; Dupas B; Laroche L; Baudouin C; Bouheraoua N
Clin Exp Ophthalmol; 2017 Jul; 45(5):455-463. PubMed ID: 27957797
[TBL] [Abstract][Full Text] [Related]
18. A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome.
Guo H; Lee C; Shah M; Janga SR; Edman MC; Klinngam W; Hamm-Alvarez SF; MacKay JA
J Control Release; 2018 Dec; 292():183-195. PubMed ID: 30359668
[TBL] [Abstract][Full Text] [Related]
19. Association between systemic activity ındex and dry eye severity in patients with primary Sjögren syndrome.
Ozek D; Kemer OE; Omma A
Arq Bras Oftalmol; 2019; 82(1):45-50. PubMed ID: 30403265
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome.
Devecı H; Kobak S
Int Ophthalmol; 2014 Oct; 34(5):1043-8. PubMed ID: 24442759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
